Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MGTX 
MeiraGTx Holdings PLC (MGTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MGTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $27.33
1 Year Target Price $27.33
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.12% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 587.27M USD | Price to earnings Ratio - | 1Y Target Price 27.33 |
Price to earnings Ratio - | 1Y Target Price 27.33 | ||
Volume (30-day avg) 5 | Beta 1.26 | 52 Weeks Range 3.85 - 8.98 | Updated Date 08/29/2025 |
52 Weeks Range 3.85 - 8.98 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.03 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.4733 | Actual -0.48 |
Profitability
Profit Margin - | Operating Margin (TTM) -1213.57% |
Management Effectiveness
Return on Assets (TTM) -42.42% | Return on Equity (TTM) -379.54% |
Valuation
Trailing PE - | Forward PE 1.61 | Enterprise Value 650854602 | Price to Sales(TTM) 15.49 |
Enterprise Value 650854602 | Price to Sales(TTM) 15.49 | ||
Enterprise Value to Revenue 17.17 | Enterprise Value to EBITDA -3.29 | Shares Outstanding 80447504 | Shares Floating 31695501 |
Shares Outstanding 80447504 | Shares Floating 31695501 | ||
Percent Insiders 24.15 | Percent Institutions 64.98 |
Upturn AI SWOT
MeiraGTx Holdings PLC
Company Overview
History and Background
MeiraGTx Holdings PLC, founded in 2015, is a gene therapy company focused on developing treatments for serious diseases. It has advanced clinical-stage programs across several therapeutic areas and has formed strategic partnerships with pharmaceutical companies.
Core Business Areas
- Ophthalmology: Developing gene therapies for inherited retinal diseases, including X-linked retinitis pigmentosa (XLRP) and achromatopsia.
- Salivary Gland Disease: Developing a gene therapy for radiation-induced xerostomia (dry mouth) following cancer treatment.
- Neurodegenerative Diseases: Developing gene therapies targeting neurodegenerative diseases, including Parkinson's disease.
Leadership and Structure
The leadership team is composed of experienced professionals in gene therapy and pharmaceutical development. The organizational structure includes research, clinical development, and commercial operations, supported by scientific advisory boards.
Top Products and Market Share
Key Offerings
- Botaretigene sparoparvovec (AAV2-hRIX):: Gene therapy candidate for XLRP (X-linked retinitis pigmentosa). Currently in late-stage development. Competitors include AGTC.
- AAV2-GAD (Nerve Growth Factor Gene Therapy):: Gene therapy candidate for radiation-induced xerostomia. Currently in clinical development. Competitors include companies developing palliative treatments for dry mouth.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly growing, driven by technological advancements and increasing regulatory approvals. It is highly competitive, with both large pharmaceutical companies and smaller biotech firms developing novel therapies.
Positioning
MeiraGTx focuses on developing gene therapies for underserved patient populations. Their strategic partnerships and platform technologies provide a competitive advantage.
Total Addressable Market (TAM)
The total addressable market for gene therapies is estimated to reach tens of billions of dollars. MeiraGTx is positioned to capture a share of this market with its pipeline of clinical-stage programs.
Upturn SWOT Analysis
Strengths
- Strong pipeline of clinical-stage gene therapy programs
- Proprietary gene therapy platform technologies
- Strategic partnerships with leading pharmaceutical companies
- Experienced management team
Weaknesses
- High R&D expenses
- Dependence on clinical trial success
- Commercialization risks
- Relatively small market cap compared to competitors
Opportunities
- Potential regulatory approvals for key pipeline assets
- Expansion of pipeline through new therapeutic areas and technologies
- Increased market adoption of gene therapies
- Potential for strategic collaborations and acquisitions
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other gene therapy companies
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- AGTC
- SPHR
- CRSP
Competitive Landscape
MeiraGTx competes with companies that are developing gene therapies, however, the gene therapy space is considered niche so these companies operate more alongside each other.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by expanding the pipeline and securing partnerships.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for XLRP and xerostomia, as well as exploring new therapeutic areas.
Summary
MeiraGTx is a gene therapy company with a promising pipeline focused on underserved patient populations, leveraging strategic partnerships and platform technologies. The success of its clinical trials is essential for future growth. Regulatory hurdles, competition, and manufacturing challenges are key risks to consider. The company needs to maintain a strong financial position to support ongoing R&D efforts. With potential regulatory approvals for key pipeline assets, MeiraGTx is well-positioned for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual circumstances and consultation with a financial professional. Market share data is estimated and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MeiraGTx Holdings PLC
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2018-06-08 | CEO, President & Director Dr. Alexandria Forbes Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 386 | Website https://meiragtx.com |
Full time employees 386 | Website https://meiragtx.com | ||
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.